ERBB2 and breast carcinoma: We recently reported results from a clinical trial in which 42 patients with operable HER-2-overexpressing breast cancer were randomly assigned to receive either 6 months of preoperative T/FEC chemotherapy (four cycles of paclitaxel followed by four cycles of 5-fluorouracil, epirubicin, and cyclophosphamide) alone or concomitant with weekly trastuzumab followed by definitive surgery.